Ingenix has successfully secured €13 million in funding to enhance its AI-driven drug development capabilities, building on a previous €9 million seed round. This investment aims to expand the company's Biological Reasoning Engine, a sophisticated AI tool designed to facilitate translational and clinical research decisions, while also increasing collaboration opportunities with pharmaceutical and biotech partners.
Founded in 2023, Ingenix is pioneering an innovative approach known as Modality Fusion, which integrates various biological data models instead of relying on a single large dataset. This method addresses a significant challenge in drug development: the diversity of biological data types—ranging from molecular to clinical levels—means that no single entity can possess all the necessary high-quality data to train a comprehensive model effectively.
CEO and co-founder Piotr Surma emphasized that the funding will enable Ingenix to extend its AI capabilities to partners who can benefit most from its applications. The company has already demonstrated the efficacy of its engine through a project in oncology, where it successfully identified promising candidate combinations for a dual-payload antibody-drug conjugate from a vast array of potential configurations.
Ingenix's approach highlights the importance of a tailored AI architecture for biological applications, moving beyond generic models. By focusing on reasoning from biological principles rather than historical data, Ingenix aims to bridge the gap between biology, chemistry, and clinical insights, ultimately enhancing the decision-making processes in drug development.